Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019
Manos Perros, President and Chief Executive Officer of
During the conference,
John O’Donnell, Senior Director of Drug Metabolism and Pharmacokinetics at Entasis, spoke and provided a poster presentation on pharmacokinetics, pharmacodynamics and dose projections for sulbactam-durlobactam. These results formed the basis of the dosing regimen tested in the Phase 2 and ongoing ATTACK Phase 3 clinical trial.
In addition, multiple poster presentations demonstrated the potent antibacterial activity of sulbactam-durlobactam against recent geographically diverse, multidrug-resistant Acinetobacter isolates, and the potent antibacterial activity of ETX0282CPDP against contemporary multidrug-resistant Enterobacteriaceae isolates.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contact
Source: Entasis Therapeutics Holdings Inc.